IL160443A0 - Sustained release of microcrystalline peptide suspension - Google Patents

Sustained release of microcrystalline peptide suspension

Info

Publication number
IL160443A0
IL160443A0 IL16044302A IL16044302A IL160443A0 IL 160443 A0 IL160443 A0 IL 160443A0 IL 16044302 A IL16044302 A IL 16044302A IL 16044302 A IL16044302 A IL 16044302A IL 160443 A0 IL160443 A0 IL 160443A0
Authority
IL
Israel
Prior art keywords
sustained release
peptide suspension
microcrystalline peptide
microcrystalline
suspension
Prior art date
Application number
IL16044302A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of IL160443A0 publication Critical patent/IL160443A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL16044302A 2001-09-06 2002-08-27 Sustained release of microcrystalline peptide suspension IL160443A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31761601P 2001-09-06 2001-09-06
PCT/EP2002/009537 WO2003022243A2 (en) 2001-09-06 2002-08-27 Sustained release of microcrystalline peptide suspensions

Publications (1)

Publication Number Publication Date
IL160443A0 true IL160443A0 (en) 2004-07-25

Family

ID=23234486

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16044302A IL160443A0 (en) 2001-09-06 2002-08-27 Sustained release of microcrystalline peptide suspension

Country Status (27)

Country Link
US (5) US7098305B2 (de)
EP (2) EP1423150B1 (de)
JP (3) JP2005504787A (de)
KR (2) KR100818904B1 (de)
CN (1) CN100386116C (de)
AR (1) AR042592A1 (de)
AT (1) ATE463258T1 (de)
AU (1) AU2002337025B2 (de)
BR (1) BR0212333A (de)
CA (1) CA2459309C (de)
CY (1) CY1118642T1 (de)
DE (1) DE60235896D1 (de)
DK (1) DK2198888T3 (de)
ES (2) ES2362505T3 (de)
HK (1) HK1062148A1 (de)
HU (1) HUP0402099A2 (de)
IL (1) IL160443A0 (de)
MX (1) MXPA04002185A (de)
NO (1) NO20040938L (de)
NZ (1) NZ531734A (de)
PL (1) PL368056A1 (de)
PT (1) PT2198888T (de)
RU (1) RU2311195C2 (de)
TW (1) TWI249409B (de)
UA (1) UA79435C2 (de)
WO (1) WO2003022243A2 (de)
ZA (1) ZA200401390B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
WO2004010957A2 (en) * 2002-07-31 2004-02-05 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
US7704977B2 (en) * 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2008071984A1 (en) * 2006-12-13 2008-06-19 Ardana Bioscience Limited Administration of the gonadotropin-releasing hormone antagonist teverelix
ES2381788T3 (es) 2007-07-16 2012-05-31 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
IL287292B (en) 2008-01-31 2022-09-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
WO2009137078A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
EP2424503B1 (de) * 2009-05-01 2017-07-05 Ferring BV Zusammensetzung zur Behandlung von Prostatakrebs
CN102711728B (zh) 2010-01-13 2016-01-20 益普生制药股份有限公司 用于延缓释放生长抑素类似物的药物组合物的制备方法
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2600887A4 (de) * 2010-07-09 2014-01-22 Amylin Pharmaceuticals Llc Mikrokristalline y-rezeptoragonisten
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
EP2823808A1 (de) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmazeutische Zusammensetzung für eine verzögerte Freisetzung von Lanreotid
EP2832361A1 (de) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Wässrige Zusammensetzungen mit verzögerter Freisetzung von LHRH-Analoga
CN104844694A (zh) * 2014-02-17 2015-08-19 深圳翰宇药业股份有限公司 一种醋酸加尼瑞克的制备方法
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
EP3689910A3 (de) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Verfahren zur verwendung von anti-cd79b-immunkonjugaten
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー/エス Glp-1アゴニスト及び腸溶コーティングを含む錠剤
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR102459469B1 (ko) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
AU2018212806A1 (en) * 2017-01-30 2019-07-18 Antev Limited A composition comprising at least one GnRH antagonist
JP2020525528A (ja) 2017-06-30 2020-08-27 アンテブ リミテッド 急性尿閉を治療するための組成物を含むシリンジ
EP3560555A1 (de) * 2018-04-26 2019-10-30 LifeArc Zusammensetzung zur behandlung einer oder mehrerer östrogenvermittelter krankheiten
MA52794A (fr) * 2018-05-28 2021-04-14 Jiangyin Usun Pharmaceutical Co Ltd Nouvelle utilisation pharmaceutique
EP3590525A1 (de) * 2018-07-05 2020-01-08 Antev Limited Teverelix-tfa-zusammensetzung
EP3590524B1 (de) * 2018-07-05 2020-11-04 Antev Limited Eine methode zur rekonstitution einer teverelix-tfa-zusammensetzung
EP3590526A1 (de) * 2018-07-05 2020-01-08 Antev Limited Lyophilisierungsverfahren und dadurch hergestelltes teverelix-tfa-lyophilisat

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2668866A (en) * 1951-08-14 1954-02-09 Shell Dev Isomerization of paraffin wax
GB1245187A (en) 1969-02-14 1971-09-08 Continental Can Co Hot melt adhesive composition
JPS5242506A (en) 1975-10-02 1977-04-02 Toa Nenryo Kogyo Kk Hydrotreating process of petroleum wax
JPS5335705A (en) * 1976-09-14 1978-04-03 Toa Nenryo Kogyo Kk Hydrogenation and purification of petroleum wax
US4186078A (en) * 1977-09-12 1980-01-29 Toa Nenryo Kogyo Kabushiki Kaisha Catalyst and process for hydrofining petroleum wax
US4239546A (en) * 1978-07-21 1980-12-16 Petrolite Corporation Hydrocarbon polymers to improve the hardness of waxes
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US4266737A (en) * 1979-11-05 1981-05-12 Arrow Converting Equipment, Inc. Air differential mandrel and method of differentially winding and rewinding tapes
US4415649A (en) * 1981-02-25 1983-11-15 E. I. Du Pont De Nemours & Co. Flexographic printing plates containing blended adhesives
US4839422A (en) * 1987-12-23 1989-06-13 Exxon Chemical Patents Inc. Ternary adhesive compositions
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
DE68928278T2 (de) 1988-02-10 1998-03-12 Tap Pharmaceuticals Inc Lhrh-analog
JP2672677B2 (ja) 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Lhrh同族体
EP0593491B1 (de) * 1991-04-25 1996-10-23 DEGHENGHI, Romano LHRH-Antagonisten
ES2127835T3 (es) * 1992-10-26 1999-05-01 Sanol Arznei Schwarz Gmbh Procedimiento para la preparacion de microcapsulas.
EP0673254A4 (de) 1992-12-04 1998-11-18 Abbott Lab Lhrh antagonistische decapeptide in position 6 modifiziert.
JP3568952B2 (ja) 1992-12-18 2004-09-22 アボット・ラボラトリーズ 5位及び6位に修飾アミノアシル残基を有するlhrh拮抗薬
CA2178592C (en) 1993-12-09 2009-07-28 Jurgen Engel Long-acting injection suspensions and a process for their preparation
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
JP3101695B2 (ja) 1996-07-24 2000-10-23 日本航空電子工業株式会社 軟x線光学素子用多層膜
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DE19813849A1 (de) * 1998-03-27 1999-09-30 Degussa Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden
CO5160256A1 (es) 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
JP4505750B2 (ja) 2006-01-27 2010-07-21 東海ゴム工業株式会社 制振装置

Also Published As

Publication number Publication date
US8415300B2 (en) 2013-04-09
EP1423150B1 (de) 2010-04-07
CA2459309A1 (en) 2003-03-20
US20060229238A1 (en) 2006-10-12
AR042592A1 (es) 2005-06-29
ZA200401390B (en) 2004-08-27
CN1551785A (zh) 2004-12-01
US20060228385A1 (en) 2006-10-12
CA2459309C (en) 2012-04-03
UA79435C2 (en) 2007-06-25
TWI249409B (en) 2006-02-21
JP5757686B2 (ja) 2015-07-29
EP1423150A2 (de) 2004-06-02
US7098305B2 (en) 2006-08-29
DE60235896D1 (de) 2010-05-20
EP2198888A2 (de) 2010-06-23
ES2362505T3 (es) 2011-07-06
NZ531734A (en) 2006-02-24
NO20040938D0 (no) 2004-03-04
KR20070107161A (ko) 2007-11-06
EP2198888B1 (de) 2016-11-02
NO20040938L (no) 2004-06-04
KR20040037077A (ko) 2004-05-04
KR100818904B1 (ko) 2008-04-04
AU2002337025B2 (en) 2006-12-07
WO2003022243A3 (en) 2003-10-30
DK2198888T3 (en) 2017-02-13
ATE463258T1 (de) 2010-04-15
EP2198888A3 (de) 2011-08-31
RU2311195C2 (ru) 2007-11-27
CY1118642T1 (el) 2017-07-12
US20110312889A1 (en) 2011-12-22
HK1062148A1 (en) 2004-10-21
ES2618777T3 (es) 2017-06-22
MXPA04002185A (es) 2004-07-23
BR0212333A (pt) 2004-09-21
HUP0402099A2 (hu) 2005-02-28
RU2004110615A (ru) 2005-05-10
WO2003022243A2 (en) 2003-03-20
JP2005504787A (ja) 2005-02-17
PT2198888T (pt) 2017-02-10
JP2013177449A (ja) 2013-09-09
US20030044463A1 (en) 2003-03-06
US20100239683A1 (en) 2010-09-23
JP2010095533A (ja) 2010-04-30
PL368056A1 (en) 2005-03-21
CN100386116C (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
IL160443A0 (en) Sustained release of microcrystalline peptide suspension
IL236190A0 (en) Controlled release of anti-infections
EP1395240A4 (de) Modifikation des verzögerten freisetzungsprofils
IL210257A0 (en) Remodeling and glycoconjugation of peptides
GB2374753B (en) Loudspeaker suspension
GB0120496D0 (en) Freeing of seized valves
TW447566U (en) Joint seat of ceiling suspension
TW484490U (en) Structural improvement of multiple-functional wrench
TW564709U (en) Improved structure of suspension decorations
HU0104370D0 (en) Honeyed schnaps of oerseg
CA92238S (en) Luminaire suspension
CA92246S (en) Luminaire suspension
TW486179U (en) Hanging structure improvement of extending socket
TW506263U (en) Structure of hanger
AU145845S (en) Fabric bear pendant
TW423278U (en) Improved structure of suspension ring
TW484379U (en) Improved structure of suspension closet
TW511829U (en) Suspension structure of speaker
TW540859U (en) Improved structure of socket
TW505004U (en) Improved structure of lamp seat
TW519201U (en) Structure of hook body
TW471732U (en) Socket of extension line
TW493490U (en) Improved structure of wrench
TW484488U (en) Improved structure of quick-withdrawn wrench
PL351273A1 (en) Novel derivatives of benzoimidazole